Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) generates frequent news flow as a clinical-stage company developing natural and engineered bacteriophage therapies targeting specific pathogenic bacteria. Company press releases and Form 8-K filings describe how BiomX advances phage cocktails and personalized phage treatments for chronic conditions, including cystic fibrosis-related lung infections and diabetic foot disease. News coverage often centers on clinical trial progress, regulatory feedback, financing transactions and strategic updates that can influence the outlook for PHGE stock.
A major theme in BiomX news is the development of its phage product candidates. For BX004, a fixed multi-phage cocktail for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, the company has reported Phase 1b/2a data, FDA Fast Track and Orphan Drug designations, initiation of a Phase 2b trial, an FDA clinical hold related to a third-party nebulizer device, and ultimately the discontinuation of the Phase 2b study after internal review and Data Monitoring Committee feedback. Separate updates detail European enrollment, FDA correspondence on potential Phase 3 pathways, and safety reviews.
News items also highlight BiomX’s diabetic foot programs. The company has announced statistically significant positive topline Phase 2 results for BX211 in diabetic foot osteomyelitis and subsequent FDA feedback supporting the development pathway for BX011, a next-generation fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections. Releases describe the rationale for prioritizing DFI, the incorporation of proprietary phages, and the role of non-dilutive funding from U.S. Defense Health Agency and Department of Navy-related sources.
Investors following PHGE can also expect updates on corporate and financial events, such as reverse stock split decisions, private placements of Series Y Convertible Preferred Stock and warrants, lease terminations at subsidiaries, and cost-cutting measures including workforce reductions. Together, these disclosures provide a detailed, evolving picture of BiomX’s clinical pipeline, regulatory interactions, capital structure and strategic alternatives. Bookmark this page to review new PHGE press releases, trial milestones and SEC-reported events as they are published.
BiomX (NYSE American: PHGE) entered an option agreement to acquire control of DFSL, a developer of LADAR (laser radar) detection systems, with the transaction estimated at approximately $45 million if closed. Consideration may include cash, a convertible promissory note, common shares and warrants exercisable at $12 per share. BiomX plans to pivot into security, defense and first-response markets; the deal is subject to Israeli regulatory approval and customary closing and shareholder approvals. DFSL’s platform claims ~99% real-world detection accuracy and is deployed in transportation and defense settings.
BiomX (NYSE: PHGE) appointed Dr. Ehud (Udi) Levi to its newly formed Advisory Board on March 30, 2026. Dr. Levi will advise as the company evaluates expansion into security, defense, aerial response and counter-UAS technologies, focusing on partnerships, transactions and new business directions.
Dr. Levi brings more than three decades in Israeli intelligence, including service in Unit 8200, leadership of the Counter-Terror Finance Office, and tenure as Deputy to the Director of the Mossad. Compensation will align with the company’s existing incentive plan.
BiomX (NYSE American: PHGE) received a March 25, 2026 notice that it does not meet NYSE American stockholders' equity minimums in Sections 1003(a)(i)-(iii). The company must submit a compliance plan by April 24, 2026 to regain compliance by September 25, 2027.
The Notice does not affect current listing or trading and the company previously disclosed a going concern paragraph in its 2025 audited financial statements.
BiomX (NYSE: PHGE) launched X Security & Defense LTD. in Israel on March 26, 2026 and will finance 2026 operations with over $3 million from internal funds. The company signed a non‑binding LOI for exclusive Israel distribution of an advanced aerial firefighting drone system.
BiomX aims to commercialize security, defense and first‑response technologies amid growing UAV emergency markets (UAV emergency responders: $3.2B 2023 → $9.6B 2032; firefighting drones: $1.8B 2023 → $4.5B 2032) and cites Israeli government emergency budgets exceeding $500 million.
BiomX (NYSE American: PHGE) CEO Michael Oster outlined a strategic and financial reset on March 19, 2026, aimed at stabilizing finances, simplifying capital structure, and unlocking future growth.
Key action: warrants from a December 2025 investment were amended to a one-year exercise period with an $1.00 exercise price, per the Form 8-K. Management is cutting non-essential costs, closing a Maryland facility, engaging banks and investors, and exploring repositioning toward defense-related opportunities.
BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.
BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.
BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock. The company said it is not aware of any undisclosed material developments in its business or affairs that would explain the activity.
BiomX noted that NYSE American contacted the company per usual practice and requested this statement. The company indicated it does not intend to provide further comment about market speculation or trading activity.
BiomX (NYSE American: PHGE) announced a private placement expected to raise approximately $3.0 million in gross proceeds on December 29, 2025. The company said proceeds will support assessment of opportunities to advance BX011 and continued evaluation of strategic alternatives. H.C. Wainwright & Co. served as exclusive placement agent. Amounts are before placement agent fees and offering expenses.
BiomX (NYSE American: PHGE) announced on December 8, 2025 that it will discontinue the Phase 2b trial of nebulized phage therapy BX004 in cystic fibrosis after an internal review and recommendations from the independent Data Monitoring Committee following unusually high rates of adverse events.
The company said it will implement cost‑cutting measures, including a significant workforce reduction, and review strategic alternatives while refocusing development efforts on its bacteriophage program BX011 for Staphylococcus aureus diabetic foot infections, subject to available resources.
BiomX (NYSE American: PHGE) said the FDA is continuing to evaluate the nebulizer device used in its BX004 Phase 2b cystic fibrosis trial and the company is working with the device manufacturer to provide requested information to lift the clinical hold. An independent Data Monitoring Committee (DMC) completed a safety review after adverse events and recommended the study continue with adjusted dosing. BiomX will update the protocol and now expects topline results in Q2 2026, with U.S. enrollment to resume once device questions are resolved.